Sarah Gheuens Sells 2,932 Shares of Agios Pharmaceuticals (NASDAQ:AGIO) Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) insider Sarah Gheuens sold 2,932 shares of the stock in a transaction that occurred on Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total transaction of $79,427.88. Following the transaction, the insider owned 64,795 shares in the company, valued at $1,755,296.55. The trade was a 4.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link.

Sarah Gheuens also recently made the following trade(s):

• On Thursday, October 30th, Sarah Gheuens sold 200 shares of Agios Pharmaceuticals stock. The stock was sold at an average price of $43.81, for a total transaction of $8,762.00.
• On Monday, October 27th, Sarah Gheuens sold 3,302 shares of Agios Pharmaceuticals stock. The shares were sold at an average price of $43.92, for a total transaction of $145,023.84.

Agios Pharmaceuticals Stock Performance

Shares of AGIO stock traded down $0.04 on Friday, hitting $27.18. 891,433 shares of the company’s stock traded hands, compared to its average volume of 1,512,286. The stock has a market capitalization of $1.58 billion, a price-to-earnings ratio of -3.88 and a beta of 0.89. The company’s fifty day simple moving average is $32.20 and its 200 day simple moving average is $35.96. Agios Pharmaceuticals, Inc. has a one year low of $22.24 and a one year high of $46.00.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share for the quarter, topping the consensus estimate of ($1.93) by $0.15. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. The business had revenue of $12.88 million during the quarter, compared to the consensus estimate of $10.49 million. During the same period in the previous year, the firm posted $16.22 earnings per share. The firm’s revenue for the quarter was up 43.3% on a year-over-year basis. As a group, sell-side analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current fiscal year.

Institutional Trading of Agios Pharmaceuticals

Large investors have recently added to or reduced their stakes in the stock. CIBC Bancorp USA Inc. purchased a new position in Agios Pharmaceuticals during the 3rd quarter valued at $242,000. CANADA LIFE ASSURANCE Co boosted its stake in shares of Agios Pharmaceuticals by 3.4% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 20,325 shares of the biopharmaceutical company’s stock valued at $796,000 after purchasing an additional 662 shares in the last quarter. TCG Crossover Management LLC increased its position in shares of Agios Pharmaceuticals by 105.2% during the third quarter. TCG Crossover Management LLC now owns 1,430,041 shares of the biopharmaceutical company’s stock valued at $57,402,000 after buying an additional 733,038 shares during the period. Alyeska Investment Group L.P. bought a new position in Agios Pharmaceuticals in the third quarter worth about $5,881,000. Finally, Voleon Capital Management LP purchased a new stake in Agios Pharmaceuticals in the third quarter worth about $268,000.

Wall Street Analyst Weigh In

Several research firms recently issued reports on AGIO. Wall Street Zen lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 22nd. Weiss Ratings restated a “sell (d)” rating on shares of Agios Pharmaceuticals in a report on Monday. Zacks Research raised shares of Agios Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 4th. Leerink Partnrs upgraded shares of Agios Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, November 20th. Finally, Royal Bank Of Canada lowered shares of Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and cut their price target for the stock from $57.00 to $28.00 in a report on Wednesday, November 19th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.89.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.